

**MAY - 4 2000**

Page -1- of 2

**510(k) SUMMARY**

**This summary of 510(k) safety and effectiveness is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92**

**The assigned 510(k) number is:** K 000 940.

**Submitted by:** InVitroCare, Inc.  
11408 Sorrento Valley Rd.  
Suite 202  
San Diego, CA 92121  
Telephone: (858) 452-1986  
Facsimile: (858) 452-1828  
E-mail: Invitroc@aol.com  
Contact: Robert E. Lovins, PhD  
Date Submitted: October 13, 1999

**Device Identification:**

Trade Name: Human Serum Albumin  
Common Name: Protein supplement for in vitro embryo culture  
Classification Name: Reproductive Media (21CFR, 886.6180)

**Predicate Device:**

Notice of Final Rule, 63 FR 48428, Docket number 97N-0335 and  
510(k) Reference Number K983584

**Description:**

Human serum albumin consists of human serum albumin from therapeutic-grade source material at a concentration of 100mg/ml in a sterile saline solution.

**Intended Use:**

Human serum albumin is intended for use in assisted reproductive procedures that require protein supplementation. These procedures include in vitro fertilization, embryo culture and growth and embryo cryopreservation.

**Design Characteristics:**

Page -2-of 2

Depending upon the procedure used, an appropriate amount of prewarmed, equilibrated HSA is withdrawn from the container and added to the culture dish and support medium. After the desired stage of embryo development is achieved, the embryo is removed from the culture dish, placed into a HEPES-buffered transfer medium and implanted into the patient. HSA is not intended to contact the patient.

**Performance Data:**

HSA is subjected to cytotoxicity testing and sperm motility/hyperactivation analysis. Each lot of HSA is also assayed by a mouse embryo assay prior to its release to market. These assays assure that the product is both functional for its intended use, the support of embryonic growth, and that no toxic components are present in the formulation. Human serum albumin has been used in a variety of clinical settings, for the intended use for a number of years. In that time the product has become one of the standard protein supplements used for the in vitro fertilization, growth and cryopreservation of human gametes and embryos.

**Additional Information:**

Mouse embryo testing will be performed as a condition of release for Human serum albumin as well as endotoxin and sterility testing. Results of all release assays will be reported on a lot-specific certificate of analysis and will be indicated on the labeling.

**Conclusion:**

The conclusion from performance testing, as well as a review of published historical information contained in the professional literature shows that Human serum albumin is suitable for its intended use and meets the criteria outlined in the Final Rule, 63 FR48428, Docket number 97N-0335.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

MAY - 4 2000

Robert E. Lovins, Ph.D.  
President  
In VitroCare, Inc.  
11408 Sorrento Valley Road, Suite 202  
San Diego, CA 92121

Re: K000940  
Human Serum Albumin (HSA)  
Dated: March 22, 2000  
Received: March 23, 2000  
Regulatory Class: II  
21 CFR §884.6180/Procode: 85 MQL

Dear Dr. Lovins:


We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4591. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsma:main.html>".

Sincerely yours,



Daniel G. Schultz, M.D.  
Captain, USPHS  
Director, Division of Reproductive,  
Abdominal, and Radiological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure(s)

InVitroCare, Inc.

March 22, 2000

Page -10-

**INDICATIONS FOR USE STATEMENT (Page 1 of 1)**510(k) number: K 000 940


Device Names: Human serum albumin

Indications for Use:

Human serum albumin is intended for use in assisted reproductive technology procedures that require protein supplementation. These procedures include in vitro fertilization, embryo culture, and embryo cryopreservation.

(PLEASE DO NOT WRITE BELOW THIS LINE- CONTINUE ON ANOTHER PAGE IF NEEDED)

---

Concurrence of CDRH, Office of Device Evaluation (ODE)  
(Division Sign-Off)  
Division of Reproductive, Abdominal, ENT,  
and Radiological Devices  
510(k) Number K000940

Prescription Use ☒  
(per 21 CFR 801.109)